A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.

Shah YB, Shaver AL, Kelly WK, Lu-Yao G. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One. 2022; 17(8):e0273826.

View in: PubMed